

# NEW ZEALAND DATA SHEET

## Vabysmo® (faricimab)

### 1. PRODUCT NAME

Vabysmo (faricimab) 120 mg/mL solution for injection for intravitreal use.

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial of 0.24 mL contains 28.8 mg of faricimab at a concentration of 120 mg/mL. This provides a usable amount to deliver a single dose of 0.05 mL solution containing 6 mg of faricimab.

Faricimab is a humanised bispecific antibody produced in mammalian Chinese Hamster Ovary (CHO) cell culture by recombinant DNA technology.

For the full list of excipients, see section 6.1 List of excipients.

### 3. PHARMACEUTICAL FORM

Solution for injection for intravitreal use.

Clear to opalescent, colourless to brownish-yellow liquid.

### 4. CLINICAL PARTICULARS

#### 4.1 THERAPEUTIC INDICATIONS

Vabysmo is indicated for the treatment of:

- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular oedema (DMO).

#### 4.2 DOSE AND METHOD OF ADMINISTRATION

For intravitreal injection only. Vabysmo must be administered by a qualified physician experienced in intravitreal injections. Each vial should only be used for the treatment of a single eye.

#### Dosage

##### *Neovascular (wet) age-related macular degeneration (nAMD)*

The recommended dose for Vabysmo is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks for the first 4 doses. Thereafter, an assessment of disease activity based on anatomic and/or visual outcomes is recommended 20 – 24 weeks after treatment initiation so treatment can be individualised (“treat-and-extend” approach). Based on these assessments, in patients without disease activity, administration of Vabysmo every 16 weeks should be considered. In patients with disease activity, treatment every 8 weeks or 12 weeks should be considered. If anatomic and/or visual outcomes change, the treatment interval should be adjusted accordingly, and interval reduction should be implemented if anatomic and/or visual

outcomes deteriorate (see section 5.1). There is limited safety data on treatment intervals of 8 weeks or less between injections (see section 4.4).

Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion, but there is no requirement for monthly monitoring between injections.

### ***Diabetic macular oedema (DMO)***

The recommended dose for Vabysmo is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks for the first 4 doses. Thereafter, treatment may be individualised using a treat-and-extend approach following an assessment of the individual patient's anatomic and/or visual outcomes. Following the outcome of this assessment, the dosing interval may remain at every 4 weeks, or may be extended in 4 week increments up to every 16 weeks. If anatomic or visual outcomes change, the treatment interval should be adjusted accordingly (see section 5.1).

Continued monitoring of disease activity and individualisation of dosing is recommended. Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's clinical judgement.

### **Duration of Treatment**

Vabysmo is intended for long-term treatment.

### **Delayed or Missed Dose**

If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician's discretion.

If visual and/or anatomic outcomes indicate that the patient is not benefitting from continued treatment, Vabysmo should be discontinued.

### **Dose Modification**

No dose modifications of Vabysmo are recommended.

### **Special populations**

#### Paediatric use

The safety and efficacy of Vabysmo in paediatric patients have not been established.

#### Geriatric use

No dose adjustment is required in patients  $\geq 65$  years of age (see section 5.2).

#### Renal Impairment

No dose adjustment is required in patients with renal impairment (see section 5.2).

#### Hepatic Impairment

No dose adjustment is required in patients with hepatic impairment (see section 5.2).

## Method of Administration

Single-use vial for intravitreal use only.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available.


Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. vision loss, eye pain, redness of the eye, photophobia, blurring of vision) without delay.

### Instructions for use and handling of Vabysmo


Vabysmo should be inspected visually for particulate matter and discoloration prior to administration. Vabysmo is a clear to opalescent and colourless to brownish-yellow liquid solution. Do not use the vial if particles, cloudiness or discoloration are visible. Allow the Vabysmo vial to reach room temperature (20 °C to 25 °C) before use. Keep the vial in the original carton to protect from light. The unopened Vabysmo vial may be stored at room temperature (25 °C) for up to 24 hours.

### *Preparation of the intravitreal injection:*


- Use aseptic technique to carry out the preparation of the intravitreal injection.
- To ensure all liquid settles at the bottom of the vial, place the vial upright on a flat surface (for about 1 minute) after removal from packaging. Gently tap the vial with your finger, as liquid may stick to the top of the vial.
- Remove the flip-off cap from the vial and disinfect the vial septum.
- Firmly attach the included 18 G x 1½ inch transfer filter needle onto a 1 mL Luer lock syringe.
- Push the transfer filter needle into the centre of the vial septum until the needle is completely inserted into the vial. Tilt the vial slightly so that the needle touches the bottom edge of the vial.




- Hold the vial slightly inclined and **slowly** withdraw all the liquid from the vial. The bevel of the transfer filter needle must be kept submerged in the liquid, to avoid introduction of air.



- Ensure that the plunger rod is drawn sufficiently back when emptying the vial, in order to completely empty the transfer filter needle.
- Disconnect the transfer filter needle from the syringe and appropriately dispose of it. **Do not use the transfer filter needle for the intravitreal injection.**
- Aseptically and firmly attach a 30 G x ½ inch injection needle onto the Luer lock syringe.
- Hold the syringe with the needle pointing up to check for air bubbles. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top.



- Carefully expel the air from the syringe and needle and **slowly** depress the plunger to align the rubber stopper tip to the 0.05 mL dose mark.



- Ensure that the injection is given **immediately** after preparation of the dose.

- Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.05 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.
- Dispose of any waste material or unused medicinal product.

### **4.3 CONTRAINDICATIONS**

Vabysmo is contraindicated in patients with:

- a known hypersensitivity to faricimab or any of the excipients listed in section 6.1. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
- ocular or periocular infections
- active intraocular inflammation.

### **4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

#### **Intravitreal injection-related reactions**

Intravitreal injections, including those with Vabysmo have been associated with endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract. Proper aseptic injection techniques must always be used when administering Vabysmo. Patients should be instructed to report any symptoms, such as pain, loss of vision, photophobia, blurred vision, floaters, or redness, suggestive of endophthalmitis or any of the above-mentioned events without delay, to permit prompt and appropriate management.

Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including those with Vabysmo. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Vabysmo while the IOP is  $\geq 30$  mmHg). In all cases, both the IOP and perfusion of the optic nerve head and/or vision must be monitored and managed appropriately.

#### **Systemic effects**

Systemic adverse events including arterial thromboembolic events have been reported following intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors and there is a theoretical risk that these may be related to VEGF inhibition.

#### **Immunogenicity**

As with all therapeutic proteins, there is the potential for immune response to Vabysmo. Patients should be instructed to report any signs or symptoms of intraocular inflammation such as vision loss, eye pain, increased sensitivity to light, floaters or worsening eye redness, which might be a clinical sign attributable to hypersensitivity (see section 4.8).

#### **Bilateral Treatment**

The safety and efficacy of Vabysmo administered in both eyes concurrently have not been studied.

### **Concomitant use of other anti-VEGF**

There are no data available on the concomitant use of Vabysmo with anti-VEGF medicinal products in the same eye.

### **Withholding treatment**

Treatment should be withheld in patients with:

- Rhegmatogenous retinal detachment, stage 3 or 4 macular holes, retinal break; treatment should not be resumed until an adequate repair has been performed.
- Treatment related decrease in Best Corrected Visual Acuity (BCVA) of  $\geq 30$  letters compared with the last assessment of visual acuity; treatment should not be resumed earlier than the next scheduled treatment.
- Performed or planned intraocular surgery within the previous or next 28 days; treatment should not be resumed earlier than the next scheduled treatment.

### **Retinal pigment epithelial tear**

Retinal pigment epithelial (RPE) tear is a complication of pigment epithelial detachment (PED) in patients with nAMD. Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for nAMD include a large and/or high pigment epithelial detachment. When initiating Vabysmo therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.

### **Populations with limited data**

There is only limited experience in the treatment of DMO patients with HbA1c over 10%, patients with high-risk proliferative diabetic retinopathy (DR), or nAMD and DMO patients with active systemic infections. There is also no experience of treatment with Vabysmo in diabetic patients with uncontrolled hypertension. This lack of information should be considered by the physician when treating such patients.

### **Effects on laboratory tests**

No data available.

## **4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

No drug-drug interaction studies have been performed with Vabysmo.

## **4.6 FERTILITY, PREGNANCY AND LACTATION**

### **Pregnancy**

There are no data from the use of Vabysmo in pregnant women.

No adverse effects were observed in a study in pregnant cynomolgus monkeys given Vabysmo intravenously throughout the period of organogenesis at doses achieving more than 500 times the predicted systemic human exposure of Vabysmo after treatment of a single eye (see section 5.3, Reproductive Toxicity).

It is not known whether Vabysmo can cross the placenta or cause harm to the fetus when administered to pregnant women. Based on the mechanism of action of VEGF and Ang-2 inhibitors, there is a potential risk to female reproductive capacity, and to embryo-fetal

development. Although the systemic exposure after ocular administration is very low, Vabysmo should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.

The safe use of Vabysmo during labour and delivery has not been established.

### **Breast-feeding**

It is not known whether Vabysmo is excreted in human breast milk. No studies have been conducted to assess the impact of Vabysmo on milk production or its presence in breast milk. Because many drugs are excreted in human milk with the potential for absorption and harm to infant growth and development exists, caution should be exercised when Vabysmo is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Vabysmo and any potential adverse effects on the breastfed child from Vabysmo.

### **Fertility**

No reproductive or fertility studies have been conducted. No effects on reproductive organs or fertility were observed in a 6-month cynomolgus monkey study with Vabysmo. VEGF inhibition has been shown to affect follicular development, corpus luteum function and fertility. Based on the mechanism of action of VEGF and Ang-2 inhibitors, there is a potential risk to female reproductive capacity, and to embryo-fetal development, however the risk is considered low due to the low systemic exposure after ocular administration (see section 5.3, Impairment of Fertility).

### **Women of childbearing potential**

Women of childbearing potential should use contraception during treatment with Vabysmo and for at least 3 months following the last dose of Vabysmo.

## **4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

Vabysmo may have a minor influence on the ability to drive and use machines due to possible temporary visual disturbances following the intravitreal injection and the associated eye examination. Patients should not drive or use machines until visual function has recovered sufficiently.

## **4.8 UNDESIRABLE EFFECTS**

### **Summary of the safety profile**

A total of 3,213 patients constituted the safety population in the four Phase III clinical studies for two years (1,926 Vabysmo treated patients; 664 in nAMD and 1,262 in DMO).

The most serious adverse reactions were uveitis (0.6%), endophthalmitis (0.5%), vitritis (0.3%), retinal tear (0.2%), rhegmatogenous retinal detachment (0.1%) and traumatic cataract (< 0.1%).

The most frequently reported adverse reactions in patients treated with Vabysmo were cataract (13%), conjunctival haemorrhage (8%), vitreous detachment (5%), IOP increased (4%), vitreous floaters (4%), eye pain (3%) and retinal pigment epithelial tear (nAMD only) (3%).

## Tabulated summary of adverse reactions from clinical trials

The safety data described below include all adverse reactions from the pooled data across four Phase III clinical studies in the indications nAMD and DMO, with a reasonable possibility of causality attribution to the injection procedure or medicinal product.

The adverse reactions are listed according to the MedDRA system organ class and ranked by frequency using the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1,000$ ).

**Table 1 Summary of adverse reactions occurring in patients treated with Vabysmo in phase III clinical trials**

MedDRA System organ class	Vabysmo n = 1,926	Frequency Category
<b>Eye Disorders</b>		
Cataract	12.7%	Very Common
Conjunctival haemorrhage	8.0%	Common
Vitreous detachment	4.8%	Common
Intraocular pressure increased	4.2%	Common
Vitreous floaters	4.1%	Common
Eye pain	3.0%	Common
RPE tear (nAMD only)	2.9%	Common
Lacrimation increased	1.1%	Common
Corneal abrasion	1.1%	Common
Eye irritation	1.0%	Common
Ocular discomfort	0.9%	Uncommon
Eye pruritus	0.9%	Uncommon
Ocular hyperaemia	0.8%	Uncommon
Vision blurred	0.8%	Uncommon
Visual acuity reduced	0.7%	Uncommon
Iritis	0.7%	Uncommon
Uveitis	0.6%	Uncommon
Endophthalmitis	0.5%	Uncommon
Sensation of foreign body	0.5%	Uncommon
Vitreous haemorrhage	0.5%	Uncommon
Iridocyclitis	0.4%	Uncommon
Vitritis	0.3%	Uncommon
Conjunctival hyperaemia	0.3%	Uncommon
Procedural pain	0.2%	Uncommon
Retinal tear	0.2%	Uncommon
Rhegmatogenous retinal detachment	0.1%	Uncommon
Visual acuity reduced transiently	< 0.1%	Rare
Traumatic cataract	< 0.1%	Rare

### **Description of selected adverse drug reactions from clinical trials**

There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the Vabysmo clinical trials in patients with nAMD and DMO. Across indications no notable difference between the groups treated with Vabysmo and the comparator were observed.

### **Immunogenicity**

In the nAMD and DMO studies, the pre-treatment incidence of anti-faricimab antibodies was approximately 1.8% and 0.8%, respectively. After initiation of dosing, anti-faricimab antibodies were detected in approximately 13.8% and 9.6% of patients with nAMD and DMO respectively, treated with Vabysmo across studies and across treatment groups. As with all therapeutic proteins, there is the potential for immune response to Vabysmo (see section 4.4).

### **Postmarketing Experience**

Rare cases of retinal vasculitis and/or retinal occlusive vasculitis have been spontaneously reported in the post-marketing setting. Retinal vasculitis and retinal occlusive vasculitis have also been reported in patients treated with intravitreal (IVT) therapies.

**Eye disorders:** retinal vasculitis, retinal occlusive vasculitis.

### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>.

## **4.9 OVERDOSE**

Doses higher than the recommended dosing regimen have not been studied. Overdosing with greater than recommended injection volume may increase intraocular pressure.

In the event of an overdose, IOP should be monitored and, if deemed necessary by the treating physician, appropriate treatment should be initiated.

For advice on the management of overdose, please contact the National Poisons Centre on 0800 POISON (0800 764766).

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 PHARMACODYNAMIC PROPERTIES**

Pharmacotherapeutic group: Ophthalmologicals, other ocular vascular disorder agents. ATC code: S01LA09

### **Mechanism of Action**

Faricimab is a humanised bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralisation of both Ang-2 and vascular endothelial growth factor A (VEGF-A).

Ang-2 causes vascular instability by promoting endothelial destabilisation, pericyte loss, and pathological angiogenesis, thus potentiating vascular leakage and inflammation. It also

sensitises blood vessels to the activity of VEGF-A resulting in further vascular destabilisation. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularisation.

By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.

### **Pharmacodynamic effect**

A suppression from baseline of median ocular free Ang-2 and free VEGF-A concentrations was observed from day 7 onwards in the four Phase III clinical studies.

#### nAMD

In Phase III studies in patients with nAMD (TENAYA, LUCERNE), objective, pre-specified visual and anatomic criteria, as well as treating physician clinical assessment, were used to guide treatment decisions at the disease activity assessment time points (week 20 and week 24).

Reductions in mean central subfield thickness (CST) were observed from baseline through week 48 with Vabysmo and were comparable to those observed with aflibercept. The mean CST reduction from baseline to the primary endpoint visits (averaged at weeks 40-48) was -137  $\mu\text{m}$  and -137  $\mu\text{m}$  for Vabysmo dosed up to every 16 weeks (Q16W) versus -129  $\mu\text{m}$  and -131  $\mu\text{m}$  with aflibercept, in TENAYA and LUCERNE, respectively. These mean CST reductions were maintained through year 2.

There was a comparable effect of Vabysmo and aflibercept on the reduction of intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED). At the primary endpoint visits (min-max, weeks 40-48), the proportion of patients in TENAYA and LUCERNE, respectively, with absence of IRF was: 76%-82% and 78%-85% in Vabysmo vs. 74%-85% and 78%-84% in aflibercept; absence of SRF: 70%-79% and 66%-78% in Vabysmo vs. 66%-78% and 62%-76% in aflibercept; absence of PED: 3%-8% and 3%-6% in Vabysmo vs. 8%-10% and 7%-9% in aflibercept. These reductions in IRF, SRF, and PED were maintained at year 2 (weeks 104-108).

At week 48, there was comparable change in total CNV lesion area from baseline across treatment arms (0.0  $\text{mm}^2$  and 0.4  $\text{mm}^2$  in Vabysmo vs. 0.4  $\text{mm}^2$  and 1.0  $\text{mm}^2$  in aflibercept, in TENAYA and LUCERNE, respectively). There was a comparable reduction in CNV leakage area from baseline across treatment arms (-3.8  $\text{mm}^2$  and -3.2  $\text{mm}^2$  in Vabysmo and -3.0  $\text{mm}^2$  and -2.2  $\text{mm}^2$  in aflibercept, in TENAYA and LUCERNE, respectively).

#### DMO

In Phase III studies in patients with DMO (YOSEMITE and RHINE), anatomic parameters related to macular oedema were part of the disease activity assessments guiding treatment decisions.

The reductions in mean CST from baseline were numerically greater in patients treated with Vabysmo every 8 weeks (Q8W) and Vabysmo up to Q16W adjustable dosing as compared to aflibercept Q8W from week 4 to week 100 in both YOSEMITE and RHINE. Greater proportions of patients in both Vabysmo arms achieved absence of IRF and absence of DMO (defined as reaching CST below 325  $\mu\text{m}$ ) as measured on Spectral Domain Optical Coherence Tomography (SD-OCT) over time in both studies, compared to the aflibercept

arm. Comparable reductions in SRF were observed across both Vabysmo and aflibercept treatment arms over time in both studies.

The mean reduction of CST from baseline to the primary endpoint visits (averaged at weeks 48-56) was 207  $\mu\text{m}$  and 197  $\mu\text{m}$  in patients treated with Vabysmo Q8W and Vabysmo up to Q16W adjustable dosing as compared to 170  $\mu\text{m}$  in aflibercept Q8W patients in YOSEMITE; results were 196  $\mu\text{m}$ , 188  $\mu\text{m}$  and 170  $\mu\text{m}$ , respectively in RHINE. These mean CST reductions were maintained through year 2. The proportion of patients with absence of DMO at primary endpoint visits (min-max, weeks 48-56) were 77%-87% and 80%-82% in patients treated with Vabysmo Q8W and Vabysmo up to Q16W adjustable dosing, as compared to 64%-71% in aflibercept Q8W patients in YOSEMITE; results were 85%-90%, 83%-87%, and 71%-77%, respectively in RHINE. These results were maintained through year 2.

At week 16, the proportion of patients with absence of IRF was numerically greater in patients receiving Vabysmo Q8W or Vabysmo up to Q16W adjustable dosing versus aflibercept Q8W dosing in both studies (YOSEMITE: 16% and 22% vs. 13%; RHINE: 20% and 20% vs. 13%). The proportions of patients with absence of IRF at primary endpoint visits (min-max, weeks 48-56) were 42%-48% and 34%-43% in patients treated with Vabysmo Q8W and Vabysmo up to Q16W adjustable dosing, as compared to 22%-25% in aflibercept Q8W patients in YOSEMITE; results were 39%-43%, 33%-41%, and 23%-29%, respectively in RHINE.

## **Clinical trials**

### Treatment of nAMD

The safety and efficacy of Vabysmo (faricimab) were assessed in two randomised, multi-center, double-masked, active comparator-controlled studies in patients with nAMD, TENAYA (NCT03823287) and LUCERNE (NCT03823300). A total of 1,329 patients were enrolled in these studies, with 1,135 (85%) patients completing the studies through week 112. A total of 1,326 patients received at least one dose (664 with Vabysmo). Patient ages ranged from 50 to 99 with a mean of 75.9 years.

In both studies, patients were randomised in a 1:1 ratio to one of two treatment arms:

- Vabysmo 6 mg up to Q16W after four initial monthly doses
- Aflibercept 2 mg Q8W after three initial monthly doses

After the first four monthly doses (weeks 0, 4, 8, and 12) patients randomised to the Vabysmo arm received Q16W, every 12 weeks (Q12W) or Q8W dosing based on an assessment of disease activity at weeks 20 and 24, using objective pre-specified visual and anatomic criteria as well as treating physician clinical assessment. Patients remained on these fixed dosing intervals until week 60 without supplemental therapy. From Week 60 onwards, patients in the Vabysmo arm moved to an adjustable dosing regimen, where the dosing interval could be increased in up to 4 week increments (up to Q16W) or could be decreased by up to 8 week increments (up to Q8W) based on an automated objective assessment of pre-specified visual and anatomic disease activity criteria. Patients in the aflibercept arm remained on Q8W dosing throughout the study period. Both studies were 112 weeks in duration.

The primary efficacy endpoint was the change from baseline in BCVA based on an average at weeks 40, 44, and 48, measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score. In both studies, Vabysmo up to Q16W treated patients had a comparable mean change from baseline in BCVA, as the patients treated with aflibercept Q8W at year 1. Meaningful vision gains from baseline were seen through week 112 in both treatment arms. Detailed results of both studies are shown in Table 2, Figure 1, and Figure 2 below.

The proportion of patients on each of the different treatment intervals at week 48 in TENAYA and LUCERNE, respectively was:

- Q16W: 46%, 45%
- Q12W: 34%, 33%
- Q8W: 20%, 22%

The proportion of patients on each of the different treatment intervals at week 112 in TENAYA and LUCERNE, respectively was:

- Q16W: 59%, 67%
- Q12W: 15%, 14%
- Q8W: 26%, 19%

**Table 2a Efficacy outcomes at the primary endpoint visits<sup>a</sup> and at year 2<sup>b</sup> in TENAYA**

Efficacy Outcomes	TENAYA			
	Year 1		Year 2	
	Vabysmo up to Q16W n = 334	Aflibercept Q8W n = 337	Vabysmo up to Q16W n = 334	Aflibercept Q8W n = 337
Mean change in BCVA as measured by ETDRS letter score from baseline (95% CI)	5.8 (4.6, 7.1)	5.1 (3.9, 6.4)	3.7 (2.1, 5.4)	3.3 (1.7, 4.9)
Difference in LS mean (95% CI)	0.7 (-1.1, 2.5)		0.4 (-1.9, 2.8)	
Proportion of patients with ≥ 15 letter gain from baseline (CMH weighted proportion, 95% CI)	20.0% (15.6%, 24.4%)	15.7% (11.9%, 19.6%)	22.5% (17.8%, 27.2%)	16.9% (12.7%, 21.1%)
Difference in CMH weighted % (95% CI)	4.3% (-1.6%, 10.1%)		5.6% (-0.7%, 11.9%)	
Proportion of patients avoiding ≥ 15 letter loss from baseline (CMH weighted proportion, 95% CI)	95.4% (93.0%, 97.7%)	94.1% (91.5%, 96.7%)	92.1% (89.1%, 95.1%)	88.6% (85.1%, 92.2%)
Difference in CMH weighted % (95% CI)	1.3% (-2.2%, 4.8%)		3.4% (-1.2%, 8.1%)	

<sup>a</sup>Average of weeks 40, 44 and 48; <sup>b</sup>Average of weeks 104, 108, 112

BCVA: Best Corrected Visual Acuity

ETDRS: Early Treatment Diabetic Retinopathy Study

CI: Confidence Interval

LS: Least Square

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

**Table 2b Efficacy outcomes at the primary endpoint visits<sup>a</sup> and at year 2<sup>b</sup> in LUCERNE**

Efficacy Outcomes	LUCERNE			
	Year 1		Year 2	
	Vabysmo up to Q16W N = 331	Aflibercept Q8W N = 327	Vabysmo up to Q16W N = 331	Aflibercept Q8W N = 327
Mean change in BCVA as measured by ETDRS letter score from baseline (95% CI)	6.6 (5.3, 7.8)	6.6 (5.3, 7.8)	5.0 (3.4, 6.6)	5.2 (3.6, 6.8)
Difference in LS mean (95% CI)	0.0 (-1.7, 1.8)		-0.2 (-2.4, 2.1)	
Proportion of patients with $\geq$ 15 letter gain from baseline (CMH weighted proportion, 95% CI)	20.2% (15.9%, 24.6%)	22.2% (17.7%, 26.8%)	22.4% (17.8%, 27.1%)	21.3% (16.8%, 25.9%)
Difference in CMH weighted % (95% CI)	-2.0% (-8.3%, 4.3%)		1.1% (-5.4%, 7.6%)	
Proportion of patients avoiding $\geq$ 15 letter loss from baseline (CMH weighted proportion, 95% CI)	95.8% (93.6%, 98.0%)	97.3% (95.5%, 99.1%)	92.9% (90.1%, 95.8%)	93.2% (90.2%, 96.2%)
Difference in CMH weighted % (95% CI)	-1.5% (-4.4%, 1.3%)		-0.2% (-4.4%, 3.9%)	

<sup>a</sup>Average of weeks 40, 44 and 48; <sup>b</sup>Average of weeks 104, 108, 112

BCVA: Best Corrected Visual Acuity


ETDRS: Early Treatment Diabetic Retinopathy Study

CI: Confidence Interval


LS: Least Square

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

**Figure 1 Mean change in visual acuity from baseline to year 2 (week 112) in TENAYA**



**Figure 2 Mean change in visual acuity from baseline to year 2 (week 112) in LUCERNE**



In both TENAYA and LUCERNE, improvements from baseline in BCVA and CST at week 60 were comparable across the two treatment arms and consistent with those seen at week 48.

At week 60, 46% of patients in TENAYA and LUCERNE were on a Q16W interval. Of these, 69% patients in both studies maintained Q16W through week 112 without an interval reduction.

At week 60, 80% and 78% of patients in TENAYA and LUCERNE, respectively, were on a  $\geq$  Q12W interval (Q16W or Q12W). Of these, 67% and 75% patients, respectively, maintained a  $\geq$  Q12W interval through week 112 without an interval reduction below Q12W.

At week 60, 33% of patients in TENAYA and LUCERNE were on a Q12W interval. Of these, 3.2% and 0% patients in TENAYA and LUCERNE, respectively maintained Q12W through week 112.

At week 60, 20% and 22% patients in TENAYA and LUCERNE, respectively, were on a Q8W interval. Of these, 34% and 30% in TENAYA and LUCERNE, respectively, maintained Q8W therapy through week 112.

Efficacy results in all evaluable subgroups (e.g. age, gender, race, baseline visual acuity, lesion type, lesion size) in each study, and in the pooled analysis, were consistent with the results in the overall populations.

In both studies, Vabysmo up to Q16W demonstrated clinically meaningful improvements from baseline to week 48 in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score that was comparable to aflibercept Q8W. Patients in Vabysmo arms in TENAYA and LUCERNE achieved a  $\geq$  4 point improvement from baseline in the NEI VFQ -25 composite score at week 48. These results were maintained at week 112.

### Treatment of DMO

The safety and efficacy of Vabysmo were assessed in two randomised, multi-centre, double-masked, active comparator-controlled 2-year studies (YOSEMITE and RHINE) in patients with DMO. A total of 1,891 patients were enrolled in the two studies with 1,622 (86%) patients completing the studies through week 100. A total of 1,887 patients were treated with at least one dose through week 56 (1,262 with Vabysmo). Patient ages ranged from 24 to 91 with a mean of 62.2 years. The overall population included both anti-VEGF naive patients (78%) and patients who had been previously treated with a VEGF inhibitor prior to study participation (22%). In both studies, patients were randomised in a 1:1:1 ratio to one of the three treatment regimens:

- Vabysmo 6 mg Q8W after the first 6 monthly doses.
- Vabysmo 6 mg up to Q16W adjustable dosing administered in 4, 8, 12 or 16 week intervals after the first 4 monthly doses.
- Aflibercept 2 mg Q8W after the first 5 monthly doses.

In the Q16W adjustable dosing arm, the dosing interval could be increased in 4-week increments or could be decreased in 4- or 8-week increments based on automated objective assessment of pre-specified visual and anatomic disease activity criteria.

Both studies demonstrated efficacy in the primary endpoint, defined as the change from baseline in BCVA at year 1 (average of the week 48, 52, and 56 visits) measured by the

ETDRS Letter Score. In both studies, Vabysmo up to Q16W treated patients had a comparable mean change from baseline in BCVA, as the patients treated with aflibercept Q8W at year 1, and these vision gains were maintained through year 2. Detailed results of both studies are shown in Table 3, Figure 3, and Figure 4 below.

After 4 initial monthly doses, the patients in the Vabysmo up to Q16W adjustable dosing arm could have received between the minimum of 6 and the maximum of 21 total injections through week 96. At week 52, 74% and 71% of patients in the Vabysmo up to Q16W adjustable dosing arm achieved a Q16W or Q12W dosing interval in YOSEMITE and RHINE, respectively (53% and 51% on Q16W, 21% and 20% on Q12W). Of these patients, 75% and 84% maintained  $\geq$  Q12W dosing without an interval reduction below Q12W through week 96; of the patients on Q16W at week 52, 70% and 82% of patients maintained Q16W dosing without an interval reduction through week 96 in YOSEMITE and RHINE, respectively. At week 96, 78% of patients in the Vabysmo up to Q16W adjustable dosing arm achieved a Q16W or Q12W dosing interval in both studies (60% and 64% on Q16W, 18% and 14% on Q12W). 4% and 6% of patients were extended to Q8W and stayed on  $\leq$  Q8W dosing intervals through week 96; 3% and 5% received only Q4W dosing in YOSEMITE and RHINE through week 96, respectively.

Detailed results from the analyses of YOSEMITE and RHINE studies are listed in Table 3 and Figures 3 and 4 below.

**Table 3a Efficacy outcomes at the year 1 primary endpoint visits<sup>a</sup> and at year 2<sup>b</sup> in YOSEMITE**

Efficacy Outcomes	YOSEMITE					
	Year 1			Year 2		
	Vabysmo Q8W n = 315	Vabysmo up to Q16W adjustable dosing n = 313	Aflibercept Q8W n = 312	Vabysmo Q8W n = 262	Vabysmo up to Q16W adjustable dosing n = 270	Aflibercept Q8W n = 259
Mean change in BCVA as measured by ETDRS letter score from baseline (97.5% CI year 1 and 95% CI year 2)	10.7 (9.4, 12.0)	11.6 (10.3, 12.9)	10.9 (9.6, 12.2)	10.7 (9.4, 12.1)	10.7 (9.4, 12.1)	11.4 (10.0, 12.7)
Difference in LS mean (97.5% CI year 1 and 95% CI year 2)	-0.2 (-2.0, 1.6)	0.7 (-1.1, 2.5)		-0.7 (-2.6, 1.2)	-0.7 (-2.5, 1.2)	
Proportion of patients who gained at least 15 letters in	29.2%	35.5%	31.8%	37.2%	38.2%	37.4%

BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	(23.9%, 34.5%)	(30.1%, 40.9%)	(26.6%, 37.0%)	(31.4%, 42.9%)	(32.8%, 43.7%)	(31.7%, 43.0%)
Difference in CMH weighted % (95% CI year 1 and year 2)	-2.6% (-10.0%, 4.9%)	3.5% (-4.0%, 11.1%)		-0.2% (-8.2%, 7.8%)	0.2% (-7.6%, 8.1%)	
Proportion of patients who avoided loss of at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	98.1% (96.5%, 99.7%)	98.6% (97.2%, 100.0%)	98.9% (97.6%, 100.0%)	97.6% (95.7%, 99.5%)	97.8% (96.1%, 99.5%)	98.0% (96.2%, 99.7%)
Difference in CMH weighted % (95% CI year 1 and year 2)	-0.8% (-2.8%, 1.3%)	-0.3% (-2.2%, 1.5%)		-0.4% (-2.9%, 2.2%)	-0.2% (-2.6%, 2.2%)	

<sup>a</sup>Average of weeks 48, 52, 56; <sup>b</sup>Average of weeks 92, 96, 100

BCVA: Best Corrected Visual Acuity

ETDRS: Early Treatment Diabetic Retinopathy Study

CI: Confidence Interval

LS: Least Square

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Note: CMH weighted % for aflibercept arm presented for Vabysmo Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for Vabysmo adjustable vs. aflibercept comparison is similar to the one shown above.

**Table 3b Efficacy outcomes at the year 1 primary endpoint visits<sup>a</sup> and at year 2<sup>b</sup> in RHINE**

Efficacy Outcomes	RHINE					
	Year 1			Year 2		
	Vabysmo Q8W n = 317	Vabysmo up to Q16W adjustable dosing n = 319	Aflibercept Q8W n = 315	Vabysmo Q8W n = 259	Vabysmo up to Q16W adjustable dosing n = 282	Aflibercept Q8W n = 254
Mean change in BCVA as measured by ETDRS letter	11.8	10.8 (9.6, 11.9)	10.3 (9.1, 11.4)	10.9 (9.5, 12.3)	10.1 (8.7, 11.5)	9.4 (7.9, 10.8)

score from baseline (97.5% CI year 1 and 95% CI year 2)	(10.6, 13.0)					
Difference in LS mean (97.5% CI year 1 and 95% CI year 2)	1.5 (-0.1, 3.2)	0.5 (-1.1, 2.1)		1.5 (-0.5, 3.6)	0.7 (-1.3, 2.7)	
Proportion of patients who gained at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	33.8% (28.4%, 39.2%)	28.5% (23.6%, 33.3%)	30.3% (25.0%, 35.5%)	39.8% (34.0%, 45.6%)	31.1% (26.1%, 36.1%)	39.0% (33.2%, 44.8%)
Difference in CMH weighted % (95% CI year 1 and year 2)	3.5% (-4.0%, 11.1%)	-2.0% (-9.1%, 5.2%)		0.8% (-7.4%, 9.0%)	-8% (-15.7%, -0.3%)	
Proportion of patients who avoided loss of at least 15 letters in BCVA from baseline (CMH weighted proportion, 95% CI year 1 and year 2)	98.9% (97.6%, 100.0%)	98.7% (97.4%, 100.0%)	98.6% (97.2%, 99.9%)	96.6% (94.4%, 98.8%)	96.8% (94.8%, 98.9%)	97.6% (95.7%, 99.5%)
Difference in CMH weighted % (95% CI year 1 and year 2)	0.3% (-1.6%, 2.1%)	0.0% (-1.8%, 1.9%)		-1.0% (-3.9%, 1.9%)	-0.7% (-3.5%, 2.0%)	

<sup>a</sup>Average of weeks 48, 52, 56; <sup>b</sup>Average of weeks 92, 96, 100

BCVA: Best Corrected Visual Acuity

ETDRS: Early Treatment Diabetic Retinopathy Study


CI: Confidence Interval

LS: Least Square


CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

Note: CMH weighted % for aflibercept arm presented for Vabysmo Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for Vabysmo adjustable vs. aflibercept comparison is similar to the one shown above.

**Figure 3 Mean change in visual acuity from baseline to year 2 (week 100) in YOSEMITE**



**Figure 4 Mean change in visual acuity from baseline to year 2 (week 100) in RHINE**



Efficacy results in patients who were anti-VEGF treatment naive prior to study participation and in all the other evaluable subgroups (e.g. by age, gender, race, baseline HbA1c, baseline visual acuity) in each study were consistent with the results in the overall populations.

Across studies, Vabysmo Q8W and up to Q16W adjustable dosing showed improvements in the pre-specified efficacy endpoint of mean change from baseline to week 52 in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score that was, comparable to aflibercept Q8W and exceeded the threshold of 4 points. Vabysmo Q8W and up to Q16W adjustable dosing also demonstrated clinically meaningful improvements in the pre-specified efficacy endpoint of change from baseline to week 52 in the NEI VFQ-25 near activities, distance activities, and driving scores, that were comparable to aflibercept Q8W. The magnitude of these changes corresponds to a 15-letter gain in BCVA. Comparable proportions of patients treated with Vabysmo Q8W, Vabysmo up to Q16W adjustable dosing, and aflibercept Q8W experienced a clinically meaningful improvement of  $\geq 4$  points from baseline to week 52 in the NEI VFQ-25 composite score, a pre-specified efficacy endpoint. These results were maintained at week 100.

An additional key efficacy outcome in DMO studies was the change in the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS-DRSS) from baseline to week 52. Of the 1,891 patients enrolled in Studies YOSEMITE and RHINE, 708 and 720 patients were evaluable for DR endpoints, respectively.

The ETDRS-DRSS scores ranged from 10 to 71 at baseline.

The majority of patients, approximately 60%, had moderate to severe non-proliferative DR (DRSS 43/47/53) at baseline.

At week 52, the proportion of patients improving by  $\geq 2$  steps on the ETDRS-DRSS was 43% to 46% across the Vabysmo Q8W and Vabysmo adjustable up to Q16W arms in both studies, compared to 36% and 47% in aflibercept Q8W arms of YOSEMITE and RHINE, respectively. The results at week 96 were 43% to 54% across the Vabysmo Q8W and Vabysmo adjustable up to Q16W arms in both studies, compared to 42% and 44% in aflibercept Q8W arms of YOSEMITE and RHINE, respectively.

Comparable results across the treatment arms were observed in both studies in the proportions of patients improving by  $\geq 3$  steps on the ETDRS-DRSS from baseline at week 52, and these results were maintained at week 96.

The results from the  $\geq 2$ -step and  $\geq 3$ -step ETDRS-DRSS improvement analyses from baseline at week 52 and at week 96 are shown in Table 4 below. The proportion of patients with a  $\geq 2$ -step improvement on the ETDRS-DRSS at baseline, week 16, week 52 and at week 96 are shown in Figures 5 and 6 below.

**Table 4a Proportion of patients who achieved  $\geq 2$ -step and  $\geq 3$ -step improvement from baseline in ETDRS-DRSS score at week 52 and at week 96 in YOSEMITE (DR evaluable population)**

	YOSEMITE					
	52 Weeks			96 Weeks		
	Vabysmo Q8W n = 237	Vabysmo up to Q16W adjustable dosing n = 242	Aflibercept Q8W n = 229	Vabysmo Q8W n = 220	Vabysmo up to Q16W adjustable dosing n = 234	Aflibercept Q8W n = 221
Proportion of patients with $\geq 2$ -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	46.0%	42.5%	35.8%	51.4%	42.8%	42.2%
Weighted Difference (97.5% CI year 1, 95% CI year 2)	10.2% (0.3%, 20.0%)	6.1% (-3.6%, 15.8%)		9.1% (0.0%, 18.2%)	0.0% (-8.9%, 8.9%)	
Proportion of patients with $\geq 3$ -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	16.8%	15.5%	14.7%	22.4%	14.6%	20.9%
Weighted Difference (95% CI year 1 and year 2)	2.1% (-4.3%, 8.6%)	0.6% (-5.8%, 6.9%)		1.5% (-6.0%, 9.0%)	-6.7% (-13.6%, 0.1%)	

ETDRS-DRSS: Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale  
 CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.

CI: Confidence Interval

Note: CMH weighted % for aflibercept arm presented for Vabysmo Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for Vabysmo adjustable vs. aflibercept comparison is similar to the one shown above.

**Table 4b Proportion of patients who achieved  $\geq 2$ -step and  $\geq 3$ -step improvement from baseline in ETDRS-DRSS score at week 52 and at week 96 in RHINE (DR evaluable population)**

	RHINE					
	52 Weeks			96 Weeks		
	Vabysmo Q8W n = 231	Vabysmo up to Q16W adjustable dosing n = 251	Aflibercept Q8W n = 238	Vabysmo Q8W n = 214	Vabysmo up to Q16W adjustable dosing n = 228	Aflibercept Q8W n = 203
Proportion of patients with $\geq 2$ -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	44.2%	43.7%	46.8%	53.5%	44.3%	43.8%
Weighted Difference (97.5% CI year 1, 95% year 2)	-2.6% (-12.6%, 7.4%)	-3.5% (-13.4%, 6.3%)		9.7% (0.4%, 19.1%)	0.3% (-8.9%, 9.5%)	
Proportion of patients with $\geq 3$ -step ETDRS-DRSS improvement from baseline (CMH weighted proportion)	16.7%	18.9%	19.4%	25.1%	19.3%	21.8%
Weighted Difference (95% CI year 1 and year 2)	-0.2% (-5.8%, 5.3%)	-1.1% (-8.0%, 5.9%)		3.3% (-4.6%, 11.3%)	-2.7% (-10.2%, 4.8%)	


ETDRS-DRSS: Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale

CMH: Cochran–Mantel–Haenszel method; a statistical test that generates an estimate of an association with a binary outcome and is used for assessment of categorical variables.


CI: Confidence Interval

Note: CMH weighted % for aflibercept arm presented for Vabysmo Q8W vs. aflibercept comparison, however the corresponding CMH weighted % for Vabysmo adjustable vs. aflibercept comparison is similar to the one shown above.

**Figure 5 Proportion of patients who achieved  $\geq 2$ -step improvement from baseline in ETDRS-DRSS score at week 16, week 52 and at week 96 in YOSEMITE**



**Figure 6 Proportion of patients who achieved  $\geq 2$ -step improvement from baseline in ETDRS-DRSS score at week 16, week 52 and at week 96 in RHINE**



The proportions of patients with new proliferative DR diagnosis (defined by ETDRS-DRSS 61 or worse) from baseline to week 96 were comparable between the Vabysmo Q8W, Vabysmo up to Q16W adjustable dosing and aflibercept Q8W dosed patients in both YOSEMITE and RHINE studies. Almost no patients required vitrectomy (0 to 4 per group) or Pan-retinal Photocoagulation (PRP) (1 to 2 per group) during the two year duration of the studies.

DR treatment effects in the subgroup of patients who were anti-VEGF naive prior to study participation were comparable to those observed in the overall DR evaluable population. Treatment effects in evaluable subgroups (e.g. by age, gender, race, baseline HbA1c, and baseline visual acuity) in each study were generally consistent with the results in the overall population.

Treatment effects in subgroups by DR severity at baseline were different and showed the greatest  $\geq 2$ -step DRSS improvements among patients with moderately severe and severe non-proliferative DR with approximately 90% of patients achieving improvements. These results were comparable across the study arms, and comparable in overall and anti-VEGF treatment-naive populations

### **Immunogenicity**

Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of incidence of antibodies to Vabysmo with the incidence of antibodies to other products may be misleading.

### **Paediatric population**

The safety and efficacy of Vabysmo in pediatric patients have not been established.

## **5.2 PHARMACOKINETIC PROPERTIES**

### **Absorption**

Vabysmo is administered intravitreally (IVT) to exert local effects in the eye. There have been no clinical studies performed with other routes of administration.

Based on a population pharmacokinetic analysis (including nAMD and DMO N = 2,246), maximum free (unbound to VEGF-A and Ang-2) faricimab plasma concentrations ( $C_{max}$ ) are estimated to occur approximately 2 days post-dose. Mean ( $\pm$  SD) plasma  $C_{max}$  are estimated 0.23 (0.07)  $\mu\text{g/mL}$  and 0.22 (0.07)  $\mu\text{g/mL}$  respectively in nAMD and in DMO/DR patients. After repeated administrations, mean plasma free faricimab trough concentrations are predicted to be 0.002-0.003  $\mu\text{g/mL}$  for Q8W dosing.

Faricimab exhibited dose-proportional pharmacokinetics (based on  $C_{max}$  and AUC) over the dose range 0.5 mg-6 mg. No accumulation of faricimab was apparent in the vitreous or in plasma following monthly dosing.

### **Distribution**

Maximum plasma free faricimab concentrations are predicted to be approximately 600 and 6000-fold lower than in aqueous and vitreous humor respectively and are below the binding affinity for VEGF and Ang-2. Therefore, systemic pharmacodynamic effects are unlikely,

further supported by the absence of significant changes in free VEGF and Ang-2 concentration in plasma upon faricimab treatment in clinical studies.

Population pharmacokinetic analysis has shown an effect of age and body weight on ocular or systemic pharmacokinetics of faricimab respectively. Both effects were considered not clinically meaningful; no dose adjustment is needed.

### **Biotransformation**

The metabolism of faricimab has not been directly studied, as monoclonal antibodies are cleared principally by catabolism.

### **Elimination**

The estimated mean apparent systemic half-life of faricimab is 7.5 days after IVT administration.

### **Special populations**

#### Renal impairment

No formal pharmacokinetic study has been conducted in patients with renal impairment. Pharmacokinetic analysis of patients in the four Phase III clinical studies of which 65% had renal impairment (mild 38%, moderate 24%, and severe 2%), revealed no differences with respect to systemic pharmacokinetics of faricimab after intravitreal administration of Vabysmo.

#### Hepatic impairment

No formal pharmacokinetic study has been conducted in patients with hepatic impairment. However, no special considerations are needed in this population because metabolism occurs via proteolysis and does not depend on hepatic function.

#### Use in the Elderly

In the four Phase III clinical studies, approximately 60% (1,149/1,929) of patients randomised to treatment with Vabysmo were  $\geq 65$  years of age. Population pharmacokinetic analysis has shown an effect of age on ocular pharmacokinetics of faricimab. The effect was considered not clinically meaningful.

#### Paediatric use

The safety and efficacy of Vabysmo in paediatric patients have not been established.

## **5.3 PRECLINICAL SAFETY DATA**

### **Genotoxicity**

No studies have been performed to establish the mutagenic potential of Vabysmo.

### **Carcinogenicity**

No carcinogenicity studies have been performed to establish the carcinogenic potential of Vabysmo.

### **Impairment of fertility**

While the anti-VEGF and anti-Ang2 components could mean a potential theoretical mechanism-based risk to reproduction, the systemic exposure stemming from intravitreal

treatment suggests that this risk may be negligible. No effects on fertility were observed in a 6-month cynomolgus monkey study with Vabysmo.

### **Reproductive Toxicity**

VEGF inhibition has been shown to cause malformations, embryo-fetal resorption, and decreased fetal weight. VEGF inhibition has also been shown to affect follicular development, corpus luteum function, and fertility. No dedicated studies addressing the effects of Ang-2 inhibition on pregnancy are available. Based on non-clinical information Ang-2 inhibition may lead to effects comparable to VEGF inhibition. Systemic exposure after ocular administration of Vabysmo is very low.

No effects on reproductive organs were observed in a 6-month cynomolgus monkey study with Vabysmo. No effects on pregnancy or fetuses were observed in an embryo-fetal development study in pregnant cynomolgus monkeys given 5 weekly IV injections of Vabysmo starting on day 20 of gestation at 1 mg/kg or 3 mg/kg. Serum exposure ( $C_{max}$ ) in monkeys at the no observed adverse effect level (NOAEL) dose of 3 mg/kg was more than 500 times that in humans at a dose of 6 mg given by intravitreal injection once every 4 weeks.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 LIST OF EXCIPIENTS**

L-histidine

Acetic acid 30% (for pH adjustment)

L-methionine

Polysorbate 20

Sodium chloride

D-Sucrose

Water for injections

### **6.2 INCOMPATIBILITIES**

In the absence of compatibility studies, this medicine must not be mixed with other medicines.

### **6.3 SHELF LIFE**

30 months

### **6.4 SPECIAL PRECAUTIONS FOR STORAGE**

Store at 2°C to 8°C in the outer carton in order to protect from light.

Do not freeze. Do not shake.

Prior to use, the unopened vial of Vabysmo may be kept at 20°C to 25°C for up to 24 hours.

Ensure that the injection is given immediately after preparation of the dose.

### **6.5 NATURE AND CONTENTS OF CONTAINER**

0.24 mL sterile, preservative-free solution in a glass vial with a coated rubber stopper sealed with an aluminum cap with a yellow plastic flip-off disk.

Pack size of 1 vial and 1 blunt transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm).

## 6.6 SPECIAL PRECAUTIONS FOR USE, HANDLING AND DISPOSAL

### Preparation for Administration

Vabysmo is a sterile, preservative-free, clear to opalescent, colorless to brownish-yellow solution.

Do not shake.

The vial contains more than the recommended dose of 6 mg. The fill volume of the vial (0.24 mL) is not to be used in total. The excess volume should be expelled prior to injection.

Injecting the entire volume of the vial results in overdose. The injection dose must be set to the 0.05 mL dose mark, i.e. 6 mg faricimab.

The contents of the vial and transfer filter needle are sterile and for single use only. Do not use if the packaging, vial and/or transfer filter needle are damaged or expired.

Unused or expired medicine should be returned to a pharmacy for disposal.

## 7. MEDICINE SCHEDULE

Prescription

## 8. SPONSOR

Roche Products (New Zealand) Limited  
PO Box 109113 Newmarket  
Auckland 1149  
NEW ZEALAND

Medical enquiries: 0800 276 243

## 9. DATE OF FIRST APPROVAL

02 October 2023

## 10. DATE OF REVISION OF THE TEXT

10 January 2024

### Summary of Changes Table

Section Changed	Summary of new information
4.2	nAMD dosing amended to include the treat and extend regimen in line with 2 year data from the nAMD clinical studies, TENAYA and LUCERNE.
4.4	Updated to include safety data from the nAMD clinical studies, TENAYA and LUCERNE.
4.8	Updated to include safety data from the nAMD clinical studies, TENAYA and LUCERNE and addition of post-marketing safety information.
5.1	Addition of 2 year data from the nAMD clinical studies, TENAYA and LUCERNE.